CABA vs EXAS · $143.9M cap vs rev $2.76B
Cabaletta Bio Inc (CABA) versus EXACT Sciences Corporation (EXAS) — a side-by-side from cached financials, not a winner call.
Cabaletta Bio Inc (CABA) is a biotechnology company listed on US.
EXACT Sciences Corporation (EXAS) is a diagnostics & research company listed on NASDAQ.
CABA does not have a complete income-statement cache yet.
Latest reported EXAS revenue for 2024-12-31 was $2.76B. Net income was -$1.03B. Revenue was up 10.4% from 2023-12-31 to 2024-12-31. EXAS currently screens at market cap $20.03B.
CABA currently screens at market cap $143.9M. EXAS currently screens at market cap $20.03B.
Not investment advice. Open the CABA and EXAS stock pages for the full models.
Not investment advice.